Heart disease AI diagnostics med-tech Artrya to list at $105m valuation

A Perth-based company aiming to alleviate the world’s leading cause of death through smarter diagnostics has lodged a prospectus with the Australian Securities and Investments Commission (ASIC), with a view to list on the ASX in November at an enterprise value of up to $105.45 million.

With…